AIM ImmunoTech Inc. has engaged Azenova, LLC, a business development consulting firm, to support its efforts to partner its pipeline programs, particularly its lead asset, Ampligen®, for the treatment of various malignant solid tumors. Azenova will assist AIM in entering into a partnership, out-license, or other transaction whereby a biopharmaceutical company takes on the further development and commercialization of Ampligen®.